David Fam, PharmD

Director, Medical Communications and Publications
Tris Pharma, Inc.
Monmouth Junction, New Jersey

Presentation(s):

• Poster Number-23 - Cebranopadol, a Novel Potent Analgesic: Binding Affinity to Opioid Receptors and In Vitro Activity

  Poster Abstracts

• Poster Number-22 - Cebranopadol, a Novel Potent Analgesic: Limitations in Physical Dependence Using Short- and Long-term Rodent Studies

  Poster Abstracts

• Poster Number-21 - Cebranopadol, a Novel Potent Analgesic: Pooled Analysis of Clinical Opiate Withdrawal Scales

  Poster Abstracts

• Poster Number-20 - Cebranopadol, a Novel Potent Analgesic: Review of Clinical Studies Conducted Across Multiple Types of Pain including Chronic Lower Back Bain, Acute Pain, Diabetic Peripheral Neuropathy, and Cancer Pain

  Poster Abstracts